A cross-border clinical network, by design.

Clinical validation is hard to retrofit. Building it in means working with hospitals and academic neurologists from the start.

A cross-border network matters for more than recruitment. It gives the evidence credibility with Belgian, Dutch, Luxembourg and German authorities at once, the regulatory geography that matters for the EU pathway.

Named advisors and active sites also make the platform a credible partner for pharmaceutical trials that need biomarker monitoring across large cohorts.